We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioFocus Signs Integrated Drug Discovery Collaboration with Boehringer Ingelheim
News

BioFocus Signs Integrated Drug Discovery Collaboration with Boehringer Ingelheim

BioFocus Signs Integrated Drug Discovery Collaboration with Boehringer Ingelheim
News

BioFocus Signs Integrated Drug Discovery Collaboration with Boehringer Ingelheim

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioFocus Signs Integrated Drug Discovery Collaboration with Boehringer Ingelheim"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Galapagos announced that its BioFocus subsidiary signed a new collaboration agreement with Boehringer Ingelheim.  

David Smith, CEO Galapagos Services, commented, “We are delighted to have secured this contract with Boehringer Ingelheim, one of the world’s leading research-based pharmaceutical companies and a new integrated drug discovery client to BioFocus.  It is testament to the strength and depth of BioFocus’ drug discovery capabilities and expertise in this particular gene family.”

Advertisement